Related references
Note: Only part of the references are listed.Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes -Systematic review and meta-analysis of randomized placebo-controlled trials
Husam M. Salah et al.
AMERICAN HEART JOURNAL (2021)
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Results of DAPA-HF
Pardeep S. Jhund et al.
CIRCULATION (2021)
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
Darren K. McGuire et al.
JAMA CARDIOLOGY (2021)
Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Dario Giugliano et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis
Dario Giugliano et al.
DIABETES OBESITY & METABOLISM (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Empagliflozin and Major Renal Outcomes in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction - A Win against a Formidable Foe
Mark H. Drazner
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials
Mei Qiu et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)
Empagliflozin in Heart Failure Diuretic and Cardiorenal Effects
Matthew Griffin et al.
CIRCULATION (2020)
Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression
Dario Giugliano et al.
DIABETES OBESITY & METABOLISM (2020)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C Wheeler et al.
Lancet Diabetes & Endocrinology (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects
Motoaki Sano et al.
CIRCULATION (2019)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Kenneth W. Mahaffey et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
Vinay Garg et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials
Dario Giugliano et al.
ENDOCRINE (2019)
SGLT2 inhibition and kidney protection
Josselin Nespoux et al.
CLINICAL SCIENCE (2018)
SGLT2 inhibition and heart failure-current concepts
Joaquim Silva Custodio et al.
HEART FAILURE REVIEWS (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Comparative performance of heterogeneity variance estimators in meta-analysis: a review of simulation studies
Dean Langan et al.
RESEARCH SYNTHESIS METHODS (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Basics of meta-analysis: I2 is not an absolute measure of heterogeneity
Michael Borenstein et al.
RESEARCH SYNTHESIS METHODS (2017)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
M. Pfister et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
ANNALS OF INTERNAL MEDICINE (2009)